Somewhat Positive Press Coverage Somewhat Unlikely to Affect Advaxis (ADXS) Stock Price
Media coverage about Advaxis (NASDAQ:ADXS) has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Advaxis earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.6894804378755 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern’s rankings:
- TESARO Inc : Corporate News Blog – EMA Grants Positive CHMP Opinion to Tesaro’s Ovarian Cancer Drug (4-traders.com)
- Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference (finance.yahoo.com)
- Cantor Fitzgerald Equities Analysts Decrease Earnings Estimates for Advaxis, Inc. (ADXS) (americanbankingnews.com)
- Advaxis, Inc. (ADXS) Rating Reiterated by HC Wainwright (americanbankingnews.com)
Advaxis (NASDAQ ADXS) opened at 4.95 on Tuesday. The company’s market cap is $200.29 million. The firm has a 50-day moving average of $6.24 and a 200 day moving average of $7.37. Advaxis has a 52-week low of $4.77 and a 52-week high of $12.66.
Advaxis (NASDAQ:ADXS) last announced its earnings results on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.27). The firm had revenue of $3.05 million for the quarter, compared to analyst estimates of $3.43 million. Advaxis had a negative return on equity of 93.54% and a negative net margin of 655.66%. Equities research analysts expect that Advaxis will post ($2.26) earnings per share for the current fiscal year.
Several research analysts have commented on ADXS shares. Cantor Fitzgerald restated an “overweight” rating and issued a $19.00 target price on shares of Advaxis in a research report on Wednesday, May 31st. HC Wainwright set a $23.00 target price on shares of Advaxis and gave the stock a “buy” rating in a research report on Wednesday, June 14th. BidaskClub upgraded shares of Advaxis from a “hold” rating to a “buy” rating in a research report on Saturday, September 9th. Finally, ValuEngine cut shares of Advaxis from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Stock Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related stocks with our FREE daily email newsletter.